Characteristic of ZMYND10 Gene’s Promoter Hypermethylation in Nasopharyngeal Carcinoma Biopsies from Vietnamese Patients


Affiliations

  • Ho Chi Minh City Open University, Department of Pharmaceutical and Medical Biotechnology, Faculty of Biotechnology, Ho Chi Minh City, Viet Nam

Abstract

Silencing of tumor suppressor gene, which caused by the DNA hypermethylation, an epigenetic modification, has been reported to be involved in human various cancers, including nasopharyngeal carcinoma. The aims of this study were to identify and evaluate the hypermethylation frequency of the ZMYND10 promoter, which located at 3p21.3, in nasopharyngeal biopsies from Vietnamese patients by Nested Methylation Specific PCR (Nested MSP). In current study, ninety tumor biopsies and ninety healthy samples, which were obtained from Cho Ray hospital, were enrolled into study. As the results, the hypermethylation frequency of ZMYND10 gene promoter was more frequent in tumor biopsies. In detail, the hypermethylation frequency of ZMYND10 gene promoter were 81.11% (73 of 90 samples), and 45.56% (41 of 90 samples) for in NPC biopsies and non-cancerous specimens. A trend toward positive association was found between hypermethylation of ZMYND10 gene and nasopharyngeal carcinoma (p < 0.0007). Additionally, the high Odds ratio (OR) and Relative risk were observed (OR = 5.13, RR = 2.49) (p < 0.0001). In conclusion, our data suggested that the hypermethylation of ZMYND10 gene promoter is a significant in nasopharyngeal carcinoma in Vietnamese patients.

Keywords

Hypermethylation, Nasopharyngeal Carcinoma, Tumor Suppressor Gene, ZMYND10

Subject Discipline

Vietnamese Nasopharyngeal carcinoma biopsy, non-cancerous samples

Full Text:

References

Sham JS, Wei WI, Zong YS, Choy D, Guo YQ, Luo Y, Lin ZX, Ng MH, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990; 335(8686):371–4. https://doi.org/10.1016/0140-6736(90)90206-K

Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765–77. https://doi.org/10.1158/10559965.EPI-06-0353 PMid:17035381

GLOBOCAN. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx

Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: A review. Epidemiol Rev. 1993; 15(2):466–85. https://doi.org/10.1093/oxfordjournals.epirev.a036130 PMid:8174667

Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821–6. https://doi.org/10.1073/pnas.93.18.9821 PMid:8790415 PMCid:PMC38513

Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001; 134(7):573–86. https://doi.org/10.7326/0003-4819-134-7-200104030-00011 PMid:11281740

Challouf S, Ziadi S, Zaghdoudi R, Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin Chim Acta. 2012; 413(7-8):795–802. https://doi.org/10.1016/j.cca.2012.01.018 PMid:22296674

Kok K, Naylor SL, Buys CH. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res. 1997; 71:27–92. https://doi.org/10.1016/S0065-230X(08)60096-2

Ji L, Minna JD, Roth JA. 3p21.3 tumor suppressor cluster: prospects for translational applications. Future Oncol. 2005; 1(1):79–92. https://doi.org/10.1517/14796694.1.1.79 PMid:16555978

Cheng Y, Ho RL, Chan KC, Kan R, Tung E, Lung HL, et al. Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma. Oncogene. 2015; 34(32):4219–28. https://doi.org/10.1038/onc.2014.353 PMid:25347745 PMCid:PMC4761643

Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene. 2007; 26(52):7283–301. https://doi.org/10.1038/sj.onc.1210547 PMid:17533367

Liu XQ, Chen HK, Zhang XS, Pan ZG, Li A, Feng QS, et al. Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. Int J Cancer. 2003; 106(1):60–5. https://doi.org/10.1002/ijc.11166 PMid:12794757

Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST, et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene. 2004; 23(27):4793–806. https://doi.org/10.1038/sj.onc.1207632 PMid:15122337

Ayadi W, Karray-Hakim H, Khabir A, Feki L, Charfi S, Boudawara T, et al. Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. Anticancer Res. 2008; 28(4B):2161–7. PMid:18751390

Epstein JB, Jones CK. Presenting signs and symptoms of nasopharyngeal carcinoma. Oral Surg Oral Med Oral Pathol. 1993; 75(1):32–6. https://doi.org/10.1016/0030-4220(93)90402-P

Hao SP, Tsang NM, Chang KP, Ueng SH. Molecular diagnosis of nasopharyngeal carcinoma: detecting LMP-1 and EBNA by nasopharyngeal swab. Otolaryngol Head Neck Surg. 2004; 131(5):651–4. https://doi.org/10.1016/j.otohns.2004.04.013 PMid:15523443

Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer

Biol. 2002; 12(6):451–62. https://doi.org/10.1016/S1044579X02000883

Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60(21):5954–8. PMid:11085511

Zhang X, Liu H, Li B, uang P, Shao J, He Z. Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. BMC Cancer. 2012; 12:267. https://doi.org/10.1186/1471-2407-12-267 PMid:22727408 PMCid:PMC3585814


Refbacks

  • There are currently no refbacks.